{"id":31185,"date":"2022-09-30T08:34:00","date_gmt":"2022-09-30T14:34:00","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=31185"},"modified":"2022-09-30T08:34:24","modified_gmt":"2022-09-30T14:34:24","slug":"brakke-viewpoint-september-30-2022","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-september-30-2022\/","title":{"rendered":"Brakke Viewpoint 30 de setembro de 2022"},"content":{"rendered":"<p>Se voc\u00ea l\u00ea este boletim todas as semanas, sabe que estamos acompanhando o progresso do Solensia (frunevetmab) da Zoetis no mercado dos Estados Unidos. Embora aprovado pelo FDA em janeiro de 2022, foi lan\u00e7ado nos EUA pela Zoetis na semana passada.<\/p>\n<p>Solensia finalmente abre o segmento de tratamento de osteoartrite para gatos nos EUA; o produto est\u00e1 previsto para ser um sucesso de p\u00fablico (&gt;$100 milh\u00f5es) quando amadurecer. Uma vez que o mercado de produtos OA em c\u00e3es tem sido um dos principais impulsionadores do crescimento na ind\u00fastria de sa\u00fade animal nos \u00faltimos 20 anos, o lan\u00e7amento do primeiro tratamento seguro e eficaz OA para gatos ter\u00e1 um forte efeito adicional. Hoje, a Zoetis permanece posicionada exclusivamente para fornecer produtos de anticorpos monoclonais na medicina veterin\u00e1ria. Tamb\u00e9m esperamos ver o lan\u00e7amento do Librela (bedinvetmab) da Zoetis nos Estados Unidos para tratar a OA em c\u00e3es nos pr\u00f3ximos 12 meses.<\/p>\n<p>A pesquisa de mercado conduzida pela Brakke no final de 2021 mostrou que mais de 90% de veterin\u00e1rios provavelmente usar\u00e3o Solensia, principalmente em gatos com OA que n\u00e3o est\u00e3o sendo tratados com um medicamento prescrito. Acreditamos que a Zoetis trabalhou duro este ano para criar consci\u00eancia sobre a OA em gatos. Hoje, esse mercado felino \u00e9 substancialmente mal atendido, portanto, o lan\u00e7amento do Solensia causar\u00e1 uma expans\u00e3o significativa do mercado. O mercado de OA em c\u00e3es j\u00e1 est\u00e1 bastante lotado, ent\u00e3o o efeito do lan\u00e7amento do Librela pode ser menos impactante, mas ainda significativo. O tempo vai dizer.<\/p>\n<p><em>Jim Kroman<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Se voc\u00ea l\u00ea este boletim informativo todas as semanas, sabe que temos acompanhado o progresso do Solensia (frunevetmab) da Zoetis no mercado dos EUA. Embora aprovado pelo FDA em janeiro de 2022, foi lan\u00e7ado nos EUA pela Zoetis na semana passada. Solensia abre finalmente o segmento de tratamento de osteoartrite para gatos nos EUA; prev\u00ea-se que o produto seja um blockbuster (&gt; $100 milh\u00f5es) quando amadurecer. Como o mercado de produtos para OA em c\u00e3es tem sido um importante motor de crescimento na ind\u00fastria de sa\u00fade animal nos \u00faltimos mais de 20 anos, o lan\u00e7amento do primeiro tratamento para OA seguro e eficaz para gatos ter\u00e1 um forte efeito adicional. Hoje a Zoetis permanece exclusivamente posicionada para fornecer produtos de anticorpos monoclonais em medicina veterin\u00e1ria. Tamb\u00e9m esperamos ver o lan\u00e7amento do Librela (bedinvetmab) da Zoetis nos EUA para tratar OA em c\u00e3es nos pr\u00f3ximos 12 meses. Uma pesquisa de mercado conduzida por Brakke no final de 2021 mostrou que &gt;90% de veterin\u00e1rios provavelmente usar\u00e3o Solensia, principalmente em gatos com OA que n\u00e3o est\u00e3o sendo tratados com medicamentos prescritos. Acreditamos que a Zoetis trabalhou arduamente este ano para conscientizar sobre a OA em gatos. Hoje este mercado felino \u00e9 substancialmente mal atendido, por isso o lan\u00e7amento do Solensia causar\u00e1 uma expans\u00e3o significativa do mercado. O mercado de OA em c\u00e3es est\u00e1 bastante lotado<\/p>\n<div class=\"view-full-post\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-september-30-2022\/\" class=\"view-full-post-btn\">Ver postagem completa<\/a><\/div>\n<p>;<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-31185","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-september-30-2022\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"If you read this newsletter each week, you know we\u2019ve been following the progress of Zoetis\u2019 Solensia (frunevetmab) into the US market.\u00a0 Although approved by the FDA in January 2022, it was just launched in the US by Zoetis this past week. Solensia opens finally opens the osteoarthritis treatment segment for cats in the US; the product is predicted to be a blockbuster (&gt;$100 million) when it matures.\u00a0 Since the market for OA products in dogs has been a major driver of growth in the animal health industry over the past 20+ years, launch of the first OA treatment safe and effective for cats will have a strong additional effect.\u00a0 Today Zoetis remains exclusively positioned to supply monoclonal antibody products in veterinary medicine.\u00a0 We also expect to see the launch of Zoetis\u2019 Librela (bedinvetmab) in the US to treat OA in dogs sometime in the next 12 months. Market research conducted by Brakke in late 2021 showed &gt;90% of veterinarians are likely to use Solensia, primarily in cats with OA that aren\u2019t being treated with a prescription medication.\u00a0 We believe that Zoetis has worked hard this year to create awareness of OA in cats.\u00a0 Today this feline market is substantially underserved, so the Solensia launch will cause significant market expansion.\u00a0 The OA market in dogs is of course quite crowdedView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-september-30-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-30T14:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-30T14:34:24+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint September 30, 2022\",\"datePublished\":\"2022-09-30T14:34:00+00:00\",\"dateModified\":\"2022-09-30T14:34:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/\"},\"wordCount\":241,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/\",\"url\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2022-09-30T14:34:00+00:00\",\"dateModified\":\"2022-09-30T14:34:24+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint September 30, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-september-30-2022\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"If you read this newsletter each week, you know we\u2019ve been following the progress of Zoetis\u2019 Solensia (frunevetmab) into the US market.\u00a0 Although approved by the FDA in January 2022, it was just launched in the US by Zoetis this past week. Solensia opens finally opens the osteoarthritis treatment segment for cats in the US; the product is predicted to be a blockbuster (&gt;$100 million) when it matures.\u00a0 Since the market for OA products in dogs has been a major driver of growth in the animal health industry over the past 20+ years, launch of the first OA treatment safe and effective for cats will have a strong additional effect.\u00a0 Today Zoetis remains exclusively positioned to supply monoclonal antibody products in veterinary medicine.\u00a0 We also expect to see the launch of Zoetis\u2019 Librela (bedinvetmab) in the US to treat OA in dogs sometime in the next 12 months. Market research conducted by Brakke in late 2021 showed &gt;90% of veterinarians are likely to use Solensia, primarily in cats with OA that aren\u2019t being treated with a prescription medication.\u00a0 We believe that Zoetis has worked hard this year to create awareness of OA in cats.\u00a0 Today this feline market is substantially underserved, so the Solensia launch will cause significant market expansion.\u00a0 The OA market in dogs is of course quite crowdedView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-september-30-2022\/","og_site_name":"Brakke Consulting Website","article_published_time":"2022-09-30T14:34:00+00:00","article_modified_time":"2022-09-30T14:34:24+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint September 30, 2022","datePublished":"2022-09-30T14:34:00+00:00","dateModified":"2022-09-30T14:34:24+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/"},"wordCount":241,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/","url":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2022-09-30T14:34:00+00:00","dateModified":"2022-09-30T14:34:24+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/brakke-viewpoint-september-30-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint September 30, 2022"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/31185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=31185"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/31185\/revisions"}],"predecessor-version":[{"id":31186,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/31185\/revisions\/31186"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=31185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=31185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=31185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}